Welcome!

News Feed Item

First Licensing Deals for Stem Cell Company Accellta

First licensing deals for stem cell company Accellta- this month the company announced that it granted worldwide, non-exclusive rights to Miltenyi Biotec to use one of Accellta’s patents in manufacturing and commercialization of Miltenyi Biotec’s proprietary medium for stem cell cultivation. Miltenyi Biotec is active worldwide and is one of the innovative leaders in products, services and clinical applications for biomedical research and cell therapy.

Several months ago, Accellta granted a similar license to Japanese nutrition and health giant, Ajinomoto. The non-exclusive license includes manufacturing and marketing rights of the medium in Japan, for both research and commercial applications. Ajinomoto has operations in 26 countries and encompasses a wide range of food and nutrition products, amino acids, chemicals and pharmaceuticals, with annual revenues exceeding USD 11 billion.

Accellta offers a range of revolutionary solutions for better affordability and quality of stem cell culturing and for developing disease models. The company was established in November 2012 by the Technion and AMIT (the Alfred Mann Institute at the Technion); its unique solutions are the result of over 15 years of pioneering research and development at the Stem Cell Center in the Rappaport Faculty of Medicine at the Technion- Israel Institute of Technology.

"The licensing deals leverage Accellta's intellectual property and allow us to offer our unique solutions to stem cell scientists and researchers worldwide, the number of which is estimated at over 100,000," says Accellta Chairman, Dr. Zeev Gilkis. "We believe these deals pave the way for more collaborations with the biomedical industry."

Since it was established, Accellta invested in creating strategic business collaborations and building physical infrastructure for clinical grade cell manufacturing. Recently it completed the construction of a state-of-the-art manufacturing facility, which will be used for industrial scale manufacturing of clinical-grade stem cells. The complex, which will serve the emerging regenerative therapy industry, is located in Haifa, Israel and includes 550 sqm of clean rooms, QC laboratories, R&D laboratories and offices.

According to Dr. Michal Amit, one of the world pioneers in stem cell research and Accellta's R&D manager, "The new manufacturing facility, together with Accellta's innovative solutions, allow both stem cell companies and research labs to culture higher quality cells in a faster, more uniform, and much more cost-effective manner."

Among Accellta's proprietary solutions: MAXELLS- a proprietary technology for cost-effective industrialization of stem cell manufacturing. Maxells uses suspension culturing and delivers unparalleled scalability and quality; SINGLES- a breakthrough technology for simple and effective culturing of stem cells as single-cells in suspension, which serves as a platform for genetic manipulation and provides enhanced uniformity and purity. In addition Accellta markets several stem cell lines and unique feeder cells.

Nowadays Accellta is focused on creating strategic partnerships with Biopharma companies and Stem Cell companies for developing economic manufacturing processes for cell products and for developing model systems for new drug screening and testing. In the future the company will also enter the market of regenerative medicine and develop therapies for currently incurable diseases.

About Accellta

Accellta develops, manufactures and markets a range of revolutionary solutions for better affordability and quality of stem cell culturing. Accellta's technologies are the result of over 15 years of pioneering research and development at the Stem Cell Center in the Technion’s Rappaport Faculty of Medicine. Accellta is a subsidiary of the Alfred Mann Institute at the Technion (AMIT) and operates a state-of-the-art manufacturing facility, laboratories and offices in Haifa, Israel. www.accellta.com

About AMIT

AMIT- Alfred Mann Institute at the Technion is the Technion hub for biomedical innovation, active since 2006, it supports the development and commercialization of exceptional bio-medical technologies conceived by Technion researchers. The institute is chaired and funded by American Billionaire and Philanthropist Dr. Alfred E. Mann. AMIT owns three startup companies- Accellta, Sealantis and Sanoculis. www.amitechnion.com

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at @DevOpsSummit at 20th Cloud Expo, Kelly Looney, director of DevOps consulting for Skytap, showed how an incremental approach to introducing containers into complex, distributed applications results in modernization with less risk and more reward. He also shared the story of how Skytap used Docker to get out of the business of managing infrastructure, and into the business of delivering innovation and business value. Attendees learned how up-front planning allows for a clean sep...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...